Sleep disturbance, cytokines, and fatigue in women with ovarian cancer

Brain, Behavior, and Immunity

Volumn 26, Issue 7, 2012, Pages 1037-1044

  Clevenger, Lauren ^a   Schrepf, Andrew ^a   Christensen, Desire ^b   DeGeest, Koen ^c   Bender, David ^c   Ahmed, Amina ^c   Goodheart, Michael J ^c,d   Penedo, Frank ^e   Lubaroff, David M ^b,c,d   Sood, Anil K ^f   Lutgendorf, Susan K ^a,c,d  

^a E11 SSH   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^e UNIVERSITY OF MIAMI   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; Circadian rhythm; Fatigue; Interleukin 6; Ovarian cancer; Sickness behaviors; Sleep

Indexed keywords

INTERLEUKIN 6;

ADULT; BEHAVIOR; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SLEEP DISORDER; SLEEP PATTERN;

ADULT; AFFECT; AGED; ANTINEOPLASTIC AGENTS; ANXIETY; BODY MASS INDEX; CYTOKINES; DEMOGRAPHY; FATIGUE; FEMALE; HEALTH BEHAVIOR; HUMANS; INTERLEUKIN-6; MIDDLE AGED; OVARIAN NEOPLASMS; SLEEP DISORDERS; TREATMENT OUTCOME;

EID: 84865657274     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2012.04.003     Document Type: Review

References (75)

1. Akechi T., Okuyama T., Akizuki N., Shimizu K., Inagaki M., Fujimori M., Shima Y., Furukawa T.A., Uchitomi Y. Associated and predictive factors of sleep disturbance in advanced cancer patients. Psychooncology 2007, 16:888-894.
2. Ancoli-Israel S., Moore P.J., Jones V. The relationship between fatigue and sleep in cancer patients: a review. Eur. J. Cancer 2001, 10:245-255.
3. Anderson N.J., Hacker E.D. Fatigue in women receiving intraperitoneal chemotherapy for ovarian cancer. A review of contributing factors. Clin. J. Oncol. Nurs. 2008, 12:445-454.
4. Andrykowski M.A., Schmidt J.E., Salsman J.M., Beacham A.O., Jacobsen P.B. Use of a case definition approach to identifying cancer-related fatigue in women undergoing adjuvant therapy for breast cancer. J. Clin. Oncol. 2005, 27:6613-6622.
5. Backhaus J., Junghanns K., Broocks A., Riemann D., Hohagen F. Test retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. J. Psychosom. Res. 2002, 53:737-740.
6. Baider L., Kaplan De-Nour A. Psychological distress and intrusive thoughts in cancer patients. J. Nerv. Ment. Dis. 1997, 185:346-348.
7. Baker F., Denniston M., Zabora J., Polland A., Dudley W.N. A POMS short form for cancer patients: psychometric and structural evaluation. Psychooncology 2002, 11:273-281.
8. Baron R.M., Kenny D.A. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J. Pers. Soc. Psychol. 1986, 51:1173-1182.
9. Beck S.L., Schwartz A.L., Towsley G., Dudley W., Barsevick A. Psychometric evaluation of the Pittsburgh Sleep Quality Index in cancer patients. J. Pain Symptom Manage. 2004, 27:140-148.
10. Berger A.M., VonEssen S., Khun B.R., Piper B.F., Farr L., Agrawal S., Lynch J.C., Higginbotham P. Feasibility of a sleep intervention during adjuvant breast cancer chemotherapy. Oncol. Nurs. Forum 2002, 29:1431-1441.
11. Born J., Lange T., Hansen K., Mölle M., Fehm H.L. Effects of sleep and circadian rhythm on human circulating immune cells. J. Immunol. 1997, 158:4454-4464.
12. Bower J.E. Cancer-related fatigue: links with inflammation in cancer patients and survivors. Brain Behav. Immun. 2007, 21:863-871.
13. Bower J.E., Ganz P.A., Desmond K.A., Rowland J.H., Meyerowitz B.E., Belin T.R. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J. Clin. Oncol. 2000, 18:743-753.
14. Bower J.E., Ganz P.A., Aziz N., Fahey J.L. Fatigue and pro-inflammatory cytokine activity in breast cancer survivors. Psychosom. Med. 2002, 64:604-611.
15. Bower J.E., Ganz P.A., Dickerson S.S., Petersen L., Aziz N., Fahey J.L. Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology 2005, 30:92-100.
16. Bradley S., Rose S., Lutgendorf S., Costanzo E., Anderson B. Quality of life and mental health in cervical and endometrial cancer survivors. Gynecol. Oncol. 2006, 100:479-486.
17. Burger R.A., Grosen E.A., Ioli G.R., Van Eden M.E., Park M., Berman M.L., Manetta A., Disaia P.J., Granger G.A., Gatanaga T. Spontaneous release of interleukin-6 by primary cultures of lymphoid and tumor cell populations purified from human ovarian carcinoma. J. Interferon Cytokine Res. 1995, 15:255-260.
18. Buysse D.J., Reynolds C.F., Monk T.H., Berman S.R., Kupfer D.J. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989, 28:193-213.
19. Campos M.P., Hassan B.J., Riechelmann R., Del Giglio A. Cancer-related fatigue: a review. Rev. Assoc. Med. Bras. 2011, 57:211-219.
20. Carpenter J.S., Andrykowski M.A. Psychometric evaluation of the Pittsburgh Sleep Quality Index. J. Psychosom. Res. 1998, 45:5-13.
21. Clevenger, L., DeGeest, K., Bender, D., Goodheart, M., Ahmed, A., Dahmoush, L., Penedo, F., Lucci III, J., Thaker, P.H., Mendez, L., Sood, A.K., Lutgendorf, S.K, under review. Sleep disturbances and quality of life in ovarian cancer patients during the first year post diagnosis.
22. Collado-Hidalgo A., Bower J.E., Ganz P.A., Cole S.W., Irwin M.R. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin. Cancer Res. 2006, 12:2759-2766.
23. Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann. N.Y. Acad. Sci. 2001, 933:222-234.
24. Dantzer R., Kelley K.W. Twenty year of research on cytokine-induced sickness behavior. Brain Behav. Immun. 2007, 21:153-160.
25. Dirksen S.R., Epstein D.R. Efficacy of an insomnia intervention on fatigue, mood, and quality of life in breast cancer survivors. J. Adv. Nurs. 2008, 61:664-675.
26. Epping-Jordan J.E., Compas B.E., Howell D.C. Predictors of cancer progression in young adult men and women: avoidance, intrusive thoughts, and psychological symptoms. Health Psychol. 1994, 13:539-547.
27. Fiorentino M.S., Ancoli-Israel S. Sleep dysfunction in patients with cancer. Curr. Treat. Options Neurol. 2007, 9:337-346.
28. Goff B.A., Mandel L., Muntz H.G., Melancon C.H. Ovarian carcinoma diagnosis. Cancer 2000, 89:2075-2086.
29. Goff B.A., Mandel L.S., Melancon C.H., Muntz H.G. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004, 291:2705-2712.
30. Golden-Kreutz D.M., Thornton L.M., Wells-DiGregorio S., Frierson G.M., Jim H.S., Carpenter K.M., Shelby R.A., Andersen B.L. Traumatic stress, perceived global stress, and life events: prospectively predicting quality of life in breast cancer patients. Health Psychol. 2005, 24:288-296.
31. Guan Z., Vgontzas A.N., Omori T., Peng X., Bixler E.O., Fang J. Interleukin-6 levels fluctuate with the light-dark cycle in the brain and peripheral tissues in rats. Brain Behav. Immun. 2005, 19:526-529.
32. Guess J., Burch J.B., Ogoussan K., Armstead C.A., Zhang H., Wagner S., Hebert J.R., Wood P., Youngstedt S.D., Hofseth L.J., Singh U.P., Xie D., Hrushesky W.J. Circadian disruption, Per3, and human cytokine secretion. Integr. Cancer Ther. 2009, 8:329-336.
33. Hann D., Winter K., Jacobsen P. Measurement of depressive symptoms in cancer patients: evaluation of the Center for Epidemiological Studies Depression scale (CES-D). J. Psychosom. Res. 1999, 46:437-443.
34. Hennessy B.T., Coleman R.L., Markman M. Ovarian cancer. Lancet 2009, 374:1371-1382.
35. Holzner B., Kemmler G., Meraner V., Maislinger A., Kopp M., Bodner T., Nguyen Van Tam D., Zeimet A.G., Fleischhacker W.W., Sperner-Unterweger B. Fatigue in ovarian carcinoma patients. A neglected issue?. Cancer 2003, 97:1564-1572.
36. Horowitz M., Wilner N., Alvarez W. Impact of events scale: a measure of subjective stress. Psychosom. Med. 1979, 41:209-218.
37. Howard J.H., Bland K.I. Current management and treatment strategies for breast cancer. Curr. Opin. Obstet. Gynecol. 2012, 24:44-48.
38. Irwin M. Effects of sleep and sleep loss on immunity and cytokines. Brain Behav. Immun. 2002, 16:503-512.
39. Irwin M.R., Wang M., Campomayor C.O., Collado-Hidalgo A., Cole S. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Arch. Intern. Med. 2006, 166:1756-1762.
40. Judd C.M., Kenny D.A. Process analysis: estimating mediation in treatment evaluations. Eval. Rev. 1981, 5:602-619.
41. Kapás L., Hong L., Cady A.B., Opp M.R., Postelthwaite A.E., Seyer J.M., Krueger J.M. Somnogenic, pyrogenic, and anorectic activities of tumor necrosis factor-alpha and TNF-alpha fragments. Am. J. Physiol. 1992, 263:R708-R715.
42. Kapsimalis F., Basta M., Varouchakis G., Gourgoulianis K., Vgontzas A., Kryger M. Cytokines and pathological sleep. Sleep Med. 2008, 9:603-614.
43. Koopman C., Nouriani B., Erickson V., Anupindi R., Butler L.D., Bachmann M.H., Sephton S.E., Spiegel D. Sleep disturbances in women with metastatic breast cancer. Breast J. 2002, 8:362-370.
44. Lofti-Jam K., Carey M., Jefford M., Schofield P., Charleson C., Aranda S. Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. J. Clin. Oncol. 2008, 26:5618-5629.
45. Mendoza T.R., Wang X.S., Cleeland C.S., Morrissey M., Johnson B.A., Wendt J.K., Huber S.L. The rapid assessment of fatigue severity in cancer patients: use of the brief fatigue inventory. Cancer 1999, 85:1186-1196.
46. Mock V., Dow K.H., Meares C.J., Grimm P.M., Dienemann J.A., Haisfield-Wolfe M.E., Quitasol W., Mitchel S., Chakravarthy A., Gage I. Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer. Oncol. Nurs. Forum 1997, 24:991-1000.
47. Motivala S.J., Irwin M.R. Sleep and immunity. Cytokine pathways linking sleep and health outcomes. Curr. Dir. Psychol. Sci. 2007, 16:21-25.
48. Motivala S.J., Sarfatti A., Olmos L., Irwin M.R. Inflammatory markers and sleep disturbance in major depression. Psychosom. Med. 2005, 67:187-194.
49. Opp M.R. Cytokines and sleep. Sleep Med. Rev. 2005, 9:355-364.
50. Opp M.R., Toth L.A. Neural-immune interactions in the regulation of sleep. Front. Biosci. 2003, 8:d768-d779.
51. Opp M.R., Obal F., Krueger J.M. Interleukin 1 alters rat sleep: temporal and dose-related effects. Am. J. Physiol. 1991, 260:R52-R58.
52. Radloff L.S. The CES-D scale: a self-report depression scale for research in the general population. Appl. Psychol. Meas. 1977, 1:385-401.
53. Redeker N.S., Lev E.L., Ruggiero J. Insomnia, fatigue, anxiety, depression and quality of life of cancer patients undergoing chemotherapy. Sch. Inq. Nurs. Pract. 2000, 14:275-290.
54. Redwine L., Hauger R.L., Gillin J.C., Irwin M. Effects of sleep and sleep deprivation on interleukin-6, growth hormone, cortisol, and melatonin levels in humans. J. Clin. Endocrinol. Metab. 2000, 85:3597-3603.
55. Redwine L., Dang J., Hall M., Irwin M. Disordered sleep, nocturnal cytokines, and immunity in alcoholics. Psychosom. Med. 2003, 65:75-85.
56. Roscoe J.A., Kaufman M.E., Matteson-Rusby S.E., Palesh O.G., Ryan J.L., Kohli S., Perlis M.L., Morrow G.R. Cancer-related fatigue and sleep disorders. Oncologist 2007, 12(suppl 1):35-42.
57. Sandadi S., Frasure H.E., Broderick M.J., Waggoner S.E., Miller J.A., von Gruenigen V.E. The effect of sleep disturbance on quality of life in women with ovarian cancer. Gynecol. Oncol. 2011, 123:351-355.
58. Savard J., Simard S., Ivers H., Morin C.M. Randomized study on the efficacy of cognitive behavioral therapy for insomnia secondary to breast cancer, part I - sleep and psychological effects. J. Clin. Oncol. 2005, 23:6083-6096.
59. Schroevers M.J., Sanderman R., van Sonderen E., Ranchor A.V. The evaluation of the Center for Epidemiologic Studies Depression (CES-D) scale: depressed and positive affect in cancer patients and healthy reference subjects. Qual. Life Res. 2000, 9:1015-1029.
60. Schubert C., Hong S., Natarajan L., Mills P.J., Dimsdale J.E. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav. Immun. 2007, 21:413-427.
61. Schwartz A.H. Validity of cancer-related fatigue instruments. Pharmacotherapy 2002, 22:1433-1441.
62. Scott H.R., McMillan D.C., Forrest L.M., Brown D.J., McArdle C.S., Milroy R. The systemic inflammatory response, weight loss, performance status, and survival in patients with inoperable non-small cell lung cancer. Br. J. Cancer 2002, 87:264-267.
63. Shacham S. A shortened version of the profile of mood states. J. Pers. Assess. 1983, 47:305-306.
64. Shapiro S.L., Bootzin R.R., Figueredo A.J., Lopez A.M., Schwartz G.E. The efficacy of mindfulness-based stress reduction in the treatment of sleep disturbances in women with breast cancer: an exploratory study. J. Psychosom. Res. 2003, 54:85-91.
65. Shearer W.T., Reuben J.M., Mullington J.M., Price N.J., Lee B.N., Smith E.O., Szuba M.P., Van Dongen H.P., Dinges D.F. Soluble TNF-alpha receptor 1 and IL-6 plasma levels in humans subjected to the sleep deprivation model of spaceflight. J. Allergy Clin. Immunol. 2001, 107:165-170.
66. Sheehan T.J., Fifield J., Reisine S., Tennen H. The measurement structure of the Center for Epidemiologic Studies Depression scale. J. Pers. Assess. 1995, 64:507-521.
67. Späth-Schwalbe E., Hansen.K., Schmidt F., Schrezenmeier H., Marshall L., Burger K., Fehm H.L., Born J. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J. Clin. Endocrinol. Metab. 1998, 83:1573-1579.
68. Sprod L.K., Palesh O.G., Janelsins M.C., Peppone L.J., Heckler C.E., Adams M.J., Morrow G.R., Mustian K.M. Exercise, sleep quality, and mediators of sleep in breast and prostate cancer patients receiving radiation therapy. Community Oncol. 2010, 7:463-471.
69. Stone R.L., Nick A.M., Armaiz-Pena N., Han H.D., Lopez G., Afshar-Kharghan V., Vasquez H.G., Urbauer D., Bottsford-Miller J., Landen C.N., Gershenson H., Matsuo K., Shahzad M.M.K., King E.R., Ahn E.H., Bond V.K., Chiu W., Wang R., Drew A.F., Collins K., DeGeest K., Lutgendorf S., Sood A.K. Bad Blood: the clinical implications, underlying mechanism, and biological significance of paraneoplastic thrombocytosis. N. Engl. J. Med. 2012, 366:610-618.
70. Tempfer C., Zeisler H., Sliutz G., Haeusler G., Hanzal E., Kainz C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol. Oncol. 1997, 66:27-30.
71. Thomas K.S., Motivala S., Olmstead R., Irwin M.R. Sleep depth and fatigue: role of cellular inflammatory system. Brain Behav. Immun. 2011, 25:53-58.
72. VanItallie T.B. Sleep and energy balance. Interactive homeostatic systems. Metabolism 2006, 55(10 suppl 2):S30-S35.
73. Vgontzas A.N., Papanicolaou D.A., Bixler E.O., Lotsikas A., Zachman K., Kales A., Prolo P., Wong M.L., Licino J., Gold P.W., Hermida R.C., Mastorakos G., Chrousos G.P. Circadian interleukin-6 secretion and quantity and depth of sleep. J. Clin. Endocrinol. Metab. 1999, 84:2603-2607.
74. Vgontzas Z.N., Bixler E.O., Lin H.M., Prolo P., Trakada G., Chrousos G.P. IL-6 and its circadian secretion in humans. Neuroimmunomodulation 2005, 12:131-140.
75. Vgontzas A.N., Pejovic S., Zoumakis E., Lin H.M., Bixler E.O., Basta M., Fang J., Sarrigiannidis A., Chrousos G.P. Daytime napping after a night of sleep loss decreases sleepiness, improves performance, and causes beneficial changes in cortisol and interleukin-6 secretion. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E253-E261.